The Impact of HFCAA on China ADR (China Healthcare Companies)
We analyzed the points in HFCAA that are difficult for China to accept.Such irreconcilable contradiction could lead to a trend of delisting from...
242 Views
China ADRs & HFCAA: Pace of Homecoming Listings Should Pick Up & Implications
The SEC naming 5 companies under the HFCAA put China ADRs under pressure last week. The news that the CAC had nixed DIDI's HK listing plans added...
648 Views
Jiangsu Hengrui Medicine (600276.CH) - Here’s when Hengrui May Recover
We analyzed the possible future development trajectory of Hengrui's performance. Due to its "DNA" and development mode, after recovering,...
277 Views
China Healthcare Weekly (Mar.11) - 2022 Government Work Report, Expensive Monkeys, Technology Patent
We listed the key points about healthcare industry in 2022 government work report. Companies should notice the skyrocketed experimental monkey...
218 Views
GEM Weekly (11 Mar 2022): Chinese Macro Data; Samsung Electronics, Swiggy, Naver, Yum China
The Global Emerging Markets weekly provides a summary of the key news and related developments impacting the largest countries and constituents of...
263 Views